IL325825A - תרכובות חדשות לטיפול בסרטן ובמחלות מטבוליות - Google Patents
תרכובות חדשות לטיפול בסרטן ובמחלות מטבוליותInfo
- Publication number
- IL325825A IL325825A IL325825A IL32582526A IL325825A IL 325825 A IL325825 A IL 325825A IL 325825 A IL325825 A IL 325825A IL 32582526 A IL32582526 A IL 32582526A IL 325825 A IL325825 A IL 325825A
- Authority
- IL
- Israel
- Prior art keywords
- cancer
- treatment
- novel compounds
- metabolic diseases
- metabolic
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/10—1,2,5-Thiadiazoles; Hydrogenated 1,2,5-thiadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Epidemiology (AREA)
- Plural Heterocyclic Compounds (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP23185489 | 2023-07-14 | ||
| EP24182972 | 2024-06-19 | ||
| PCT/EP2024/069828 WO2025016906A1 (en) | 2023-07-14 | 2024-07-12 | Novel compounds for the treatment of cancer and metabolic diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL325825A true IL325825A (he) | 2026-03-01 |
Family
ID=91856247
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL325828A IL325828A (he) | 2023-07-14 | 2024-07-12 | תרכובות חדשות לטיפול בסרטן ובמחלות מטבוליות |
| IL325825A IL325825A (he) | 2023-07-14 | 2024-07-12 | תרכובות חדשות לטיפול בסרטן ובמחלות מטבוליות |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL325828A IL325828A (he) | 2023-07-14 | 2024-07-12 | תרכובות חדשות לטיפול בסרטן ובמחלות מטבוליות |
Country Status (9)
| Country | Link |
|---|---|
| EP (2) | EP4743447A1 (he) |
| KR (2) | KR20260040037A (he) |
| CN (2) | CN121568928A (he) |
| AR (2) | AR133250A1 (he) |
| AU (2) | AU2024294886A1 (he) |
| CO (2) | CO2026000332A2 (he) |
| IL (2) | IL325828A (he) |
| TW (2) | TW202519209A (he) |
| WO (2) | WO2025016906A1 (he) |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5543523A (en) | 1994-11-15 | 1996-08-06 | Regents Of The University Of Minnesota | Method and intermediates for the synthesis of korupensamines |
| BRPI0619547A2 (pt) * | 2005-12-08 | 2011-10-04 | Novartis Ag | 1,1,3-trioxo-1,2,5-tiadiazolidinas, composição farmacêutica e uso das mesmas |
| UA94921C2 (en) * | 2005-12-08 | 2011-06-25 | Новартис Аг | 1-orthofluorophenyl substituted 1, 2, 5-thiazolidinedione derivatives as ptp-as inhibitors |
| AU2020234712B2 (en) | 2019-03-14 | 2025-12-04 | Abbvie Inc. | Protein tyrosine phosphatase inhibitors and methods of use thereof |
| MX2022007441A (es) | 2019-12-18 | 2022-09-02 | Calico Life Sciences Llc | Inhibidores de proteína tirosina fosfatasa y sus métodos de uso. |
| WO2021127586A1 (en) | 2019-12-20 | 2021-06-24 | Calico Life Sciences Llc | Protein tyrosine phosphatase degraders and methods of use thereof |
| CN117279913A (zh) | 2021-03-11 | 2023-12-22 | 金橘生物科技公司 | 杂环化合物及其用途 |
| AU2022397239A1 (en) | 2021-11-23 | 2024-06-06 | Kumquat Biosciences Inc. | Hetero-atom containing compounds and uses thereof |
| CN117658947B (zh) * | 2022-09-06 | 2026-03-06 | 杭州中美华东制药有限公司 | 蛋白酪氨酸磷酸酶抑制作用的5-(取代芳基)-1,2,5-噻二唑啉-3-酮类化合物 |
-
2024
- 2024-07-12 KR KR1020267004414A patent/KR20260040037A/ko active Pending
- 2024-07-12 KR KR1020267004409A patent/KR20260037131A/ko active Pending
- 2024-07-12 IL IL325828A patent/IL325828A/he unknown
- 2024-07-12 AU AU2024294886A patent/AU2024294886A1/en active Pending
- 2024-07-12 AR ARP240101826A patent/AR133250A1/es unknown
- 2024-07-12 TW TW113126300A patent/TW202519209A/zh unknown
- 2024-07-12 EP EP24740175.5A patent/EP4743447A1/en active Pending
- 2024-07-12 TW TW113126297A patent/TW202519514A/zh unknown
- 2024-07-12 AR ARP240101825A patent/AR133249A1/es unknown
- 2024-07-12 WO PCT/EP2024/069828 patent/WO2025016906A1/en not_active Ceased
- 2024-07-12 CN CN202480044245.6A patent/CN121568928A/zh active Pending
- 2024-07-12 IL IL325825A patent/IL325825A/he unknown
- 2024-07-12 CN CN202480044349.7A patent/CN121568929A/zh active Pending
- 2024-07-12 EP EP24743789.0A patent/EP4743178A1/en active Pending
- 2024-07-12 WO PCT/EP2024/069833 patent/WO2025016909A1/en not_active Ceased
- 2024-07-12 AU AU2024296172A patent/AU2024296172A1/en active Pending
-
2026
- 2026-01-14 CO CONC2026/0000332A patent/CO2026000332A2/es unknown
- 2026-01-15 CO CONC2026/0000413A patent/CO2026000413A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN121568929A (zh) | 2026-02-24 |
| EP4743178A1 (en) | 2026-05-20 |
| TW202519209A (zh) | 2025-05-16 |
| IL325828A (he) | 2026-03-01 |
| AR133250A1 (es) | 2025-09-10 |
| AR133249A1 (es) | 2025-09-10 |
| TW202519514A (zh) | 2025-05-16 |
| EP4743447A1 (en) | 2026-05-20 |
| CO2026000332A2 (es) | 2026-02-02 |
| WO2025016909A1 (en) | 2025-01-23 |
| AU2024296172A1 (en) | 2026-03-05 |
| CO2026000413A2 (es) | 2026-02-02 |
| AU2024294886A1 (en) | 2026-03-05 |
| KR20260037131A (ko) | 2026-03-17 |
| CN121568928A (zh) | 2026-02-24 |
| WO2025016906A1 (en) | 2025-01-23 |
| KR20260040037A (ko) | 2026-03-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL327418A (he) | מעכבי ras-pi3k לטיפול בסרטן ובמחלות אימונולוגיות | |
| GB201907616D0 (en) | Novel compounds and pharmaceutical compositons thereof for the treatment of diseases | |
| ES3065771T3 (en) | Substituted oxoisoindoline compounds for the treatment of cancer | |
| EP4010081A4 (en) | POLYTHERAPY FOR THE TREATMENT OF CANCER | |
| ZA202206743B (en) | Therapy for the treatment of cancer | |
| GB202010464D0 (en) | Novel compounds and pharmaceutical compositions thereof for the treatment of diseases | |
| GB202018015D0 (en) | Composition and methods for the treatment of intestinal cancer | |
| GB202116903D0 (en) | Lasofoxifene treatment of aromatase-resistant er+ cancer | |
| PL3924340T3 (pl) | Pochodne indazolilo-izoksazolu do leczenia chorób, takich jak rak | |
| AU2024216821A1 (en) | Rifabutin analogs for the treatment of bacterial diseases | |
| EP4157246B8 (en) | Therapeutic combination for the treatment of breast cancer | |
| IL325828A (he) | תרכובות חדשות לטיפול בסרטן ובמחלות מטבוליות | |
| CA3295825A1 (en) | Novel compounds for the treatment of cancer and metabolic diseases | |
| CA3295889A1 (en) | Novel compounds for the treatment of cancer and metabolic diseases | |
| IL314687A (he) | טיפול בסרטן | |
| GB202503453D0 (en) | Compounds for the treatment of skin diseases | |
| GB202403324D0 (en) | Compounds for the treatment of skin diseases | |
| IL320482A (he) | טיפול משולב לטיפול בסרטן | |
| CA3273751A1 (en) | Compositions and methods for treatment of cancer and metabolic disease | |
| HK40130970A (en) | Combination therapy for the treatment of cancer | |
| CA3271803A1 (en) | Combination therapy for the treatment of cancer | |
| HK40129364A (en) | Combination therapy for the treatment of cancer | |
| HK40114518A (en) | Combination therapy for the treatment of cancer | |
| GB202311976D0 (en) | Treatment of cancer | |
| GB202218181D0 (en) | Treatment of cancer |